Filing Flows › Comparisons › CTKB vs ALMR
Cytek Biosciences vs Alamar Biosciences: CTKB and ALMR compared
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $33.5M for Alamar Biosciences (Q3 2026). Alamar Biosciences is growing faster (+68% against +2% a year earlier). Cytek Biosciences is more profitable, with an operating margin of -15.8% against -45.1%.
Where the money goes: CTKB and ALMR
Cytek Biosciences (CTKB) · Q3 2026
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Alamar Biosciences (ALMR) · Q3 2026
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Cytek Biosciences (CTKB) | Alamar Biosciences (ALMR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $53.2M | $33.5M |
| Revenue growth, Y/Y | +2% | +68% |
| Operating margin | -15.8% | -45.1% |
| Net earnings | −$6.1M | −$13.3M |
| Net margin | -11.5% | -39.8% |
| Operating cash flow | −$4.5M | −$14.7M |
Where the revenue comes from
Cytek Biosciences
- Product: $37.2M (70%)
- Service: $16.1M (30%)
Alamar Biosciences
- Product: $26.3M (78%)
- Service Other: $7.2M (22%)
Questions
Which is bigger, Cytek Biosciences or Alamar Biosciences?
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $33.5M for Alamar Biosciences (Q3 2026).
Is Cytek Biosciences or Alamar Biosciences growing faster?
Alamar Biosciences is growing faster (+68% against +2% a year earlier).
Which is more profitable, Cytek Biosciences or Alamar Biosciences?
Cytek Biosciences is more profitable, with an operating margin of -15.8% against -45.1%.
More: Cytek Biosciences earnings · how Cytek Biosciences makes money · Alamar Biosciences earnings · how Alamar Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.